Table 3.

Switching between treatment modalities during the study period

Switches, N = 946	Denosumab	Oral BP	iv BP	SR	Other	No treatment
Denosumab	–	7 (0.7%)	1 (0.1%)	1 (0.1%)	0	137 (14.5%)
Oral BPs	48 (5.1%)	–	7 (0.7%)	2 (0.2%)	2 (0.2%)	575 (60.8%)
iv BPs	12 (1.3%)	6 (0.6%)	–	1 (0.1%)	0	47 (5.0%)
SR	6 (0.6%)	5 (0.5%)	0	–	0	62 (6.6%)
Other	0	1 (0.1%)	0	0	–	4 (0.4%)
No treatment	16 (1.7%)	2 (0.2%)	1 (0.1%)	2 (0.2%)	1 (0.1%)	–

SR strontium ranelate